Natera, Inc. (NTRA) Stock Analysis
Range Bound setup
Healthcare · Diagnostics & Research
Sell if holding. Momentum 3.7/10 is below the 5.0 floor at $203.70 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: Panorama NIPT, Horizon, and Signatera (majority of revenue); Concentration risk — Counterparty: DNAnexus (sole cloud platform for algorithms).
Natera is a diagnostics company commercializing cfDNA-based tests for oncology (Signatera MRD), women's health (Panorama NIPT, Horizon carrier screening), and organ health (Prospera transplant rejection). Revenue reached $2,306.1M in 2025 ($2,295.8M product revenue), processing... Read more
Sell if holding. Momentum 3.7/10 is below the 5.0 floor at $203.70 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: Panorama NIPT, Horizon, and Signatera (majority of revenue); Concentration risk — Counterparty: DNAnexus (sole cloud platform for algorithms). Chart setup: RSI 51 mid-range, Bollinger mid-band. Score 5.7/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Natera, Inc.
Latest news
- Natera shares slide as investors weigh near-term sentiment headwinds ahead of upcoming earnings - Quiver Quantitative — Quiver Quantitative negative
- Natera, Inc. (NASDAQ:NTRA) Short Interest Down 22.5% in April - MarketBeat — MarketBeat negative
- Should You Be Bullish on Natera (NTRA)? - Yahoo Finance — Yahoo Finance positive
- What To Expect From Natera’s (NTRA) Q4 Earnings - StockStory — StockStory neutral
- Natera president John Fesko sells $59,992 of NTRA shares - Investing.com — Investing.com negative
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductPanorama NIPT, Horizon, and Signatera (majority of revenue)10-K Item 1A: 'the significant majority of our revenues are derived from sales of our Panorama NIPT, our Horizon carrier screening, or HCS, test, and our Signatera test'
- HIGHcounterpartyDNAnexus (sole cloud platform for algorithms)10-K Item 1: 'We do not have any backup cloud platform, server or other means to host our algorithms, and may be unable to find and implement an alternative platform that is satisfactory for our needs on commercially reasonable terms, in a timely manner, or at all'
Material Events(8-K, last 90d)
- 2026-04-01Item 5.02LOWEric Rubin appointed as Class I director to the Board effective March 26, 2026; Board expanded from ten to eleven members. Dr. Rubin joins Nominating, Corporate Governance and Compliance Committee. No arrangement cited for selection.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·2 ceiling hits
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.7/10 is below the 5.0 floor at $203.70 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: Panorama NIPT, Horizon, and Signatera (majority of revenue); Concentration risk — Counterparty: DNAnexus (sole cloud platform for algorithms). Chart setup: RSI 51 mid-range, Bollinger mid-band. Prior stop was $182.32. Score 5.7/10, moderate confidence.
Take-profit target: $234.80 (+19.8% upside). Prior stop was $182.32. Stop-loss: $182.32.
Concentration risk — Product: Panorama NIPT, Horizon, and Signatera (majority of revenue); Concentration risk — Counterparty: DNAnexus (sole cloud platform for algorithms); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7).
Natera, Inc. trades at a P/E of N/A (forward -518.5). TrendMatrix value score: 5.5/10. Verdict: Sell.
28 analysts cover NTRA with a consensus score of 4.3/5. Average price target: $261.
What does Natera, Inc. do?Natera is a diagnostics company commercializing cfDNA-based tests for oncology (Signatera MRD), women's health...
Natera is a diagnostics company commercializing cfDNA-based tests for oncology (Signatera MRD), women's health (Panorama NIPT, Horizon carrier screening), and organ health (Prospera transplant rejection). Revenue reached $2,306.1M in 2025 ($2,295.8M product revenue), processing approximately 3.5 million tests. The company markets tests through a direct U.S. sales force and 100+ international lab/distribution partners.